VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Vivos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.13+0.00 (+2.90%)
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Vivos Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.71M | $229.23M |
| Enterprise Value | $8.91M | $194.73M |
| PS Ratio | 0.13 | 3.14 |
Enterprise value
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.43 | 2.93 |
Income (trailing twelve months)
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Revenue | $20.90M | $102.39M |
| Gross Profit | $12.94M | $60.36M |
| Operating Income | -$22.56M | -$4.31M |
| Pretax Income | -$25.63M | -$2.26M |
| Net Income | -$25.46M | -$6.57M |
| EBITDA | -$20.77M | -$1.98M |
| EPS (Diluted) | -$1.88 | -$0.07 |
Margins
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 61.9% | 55.1% |
| Operating Margin | -107.9% | -6.04% |
| Pretax Margin | -122.6% | -4.11% |
| Profit Margin | -121.8% | -10.5% |
| EBITDA Margin | -99.4% | -2.67% |
| FCF Margin | -91.0% | -0.30% |
Returns
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -6629.4% | -19.2% |
| Return on Assets (ROA) | -101.5% | -13.3% |
| Return on Invested Capital (ROIC) | -334.7% | -4.11% |
| Return on Capital Employed (ROCE) | -600.7% | -9.07% |
Growth
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 45.2% | 8.85% |
| Revenue Growth (3Y CAGR) | 2.87% | 7.08% |
| Revenue Growth (5Y CAGR) | 5.95% | 11.8% |
Balance sheet
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.77M | $37.33M |
| Total Debt | $8.14M | $72.66M |
| Net Cash (Debt) | -$6.36M | $3.92M |
| Net Cash Per Share | -$0.32 | $0.28 |
| Equity (Book Value) | -$3.82M | $57.36M |
| Book Value Per Share | -$0.19 | $2.81 |
| Tangible Book Value | -$16.03M | $10.71M |
| Working Capital | -$16.18M | $54.64M |
Financial position
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.21 | 2.50 |
| Quick Ratio | 0.16 | 1.54 |
| Interest Coverage | -6.44 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$17.13M | -$653.46K |
| Capital Expenditures | -$1.88M | -$3.69M |
| Free Cash Flow | -$19.01M | -$835.02K |
| FCF Per Share | -$0.95 | -$0.02 |
Efficiency
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.83 | 0.59 |
| Revenue Per Employee | $77.99K | $322.75K |
| Profits Per Employee | -$94.99K | -$52.11K |
| Employee Count | 268 | 197 |
Dividends and yields
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -938.0% | -6.92% |
| FCF Yield | -700.6% | -0.62% |
| Buyback Yield | -216.0% | 0.78% |
| Shareholder Yield | -216.0% | 0.84% |
Shares
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 20,118,000 | 44,856,700 |
| Shares Change (YoY) | 76.7% | 3.35% |
| Shares Change (QoQ) | 7.75% | 0.27% |
| Float | 14,009,000 | 36,934,400 |
| Shares Held by Insiders | 30.4% | 10.6% |
| Shares Held by Institutions | 2.64% | 63.5% |
Scores
| Measure | Vivos Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -11.00 | 1.95 |
| Piotroski F-Score | 3 | 5 |
| Beneish M-Score | -1.30 | -2.64 |
Calculated by StockData from Vivos Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.